By Dr Charles Edo de Bock

Journal articles

Toscan CE; McCalmont H; Ashoorzadeh A; Lin X; Fu Z; Doculara L; Kosasih HJ; Cadiz R; Zhou A; Williams S; Evans K; Khalili F; Cai R; Yeats KL; Gifford AJ; Pickford R; Mayoh C; Xie J; Henderson MJ; Trahair TN; Patterson AV; Smaill JB; de Bock CE; Lock RB, 2024, 'The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia', Blood Cancer Journal, 14, pp. 192, http://dx.doi.org/10.1038/s41408-024-01180-x

Beck D; Cao H; Tian F; Huang Y; Jiang M; Zhao H; Tai X; Xu W; Kosasih HJ; Kealy DJ; Zhao W; Taylor SJ; Couttas TA; Song G; Chacon-Fajardo D; Walia Y; Wang M; Dowle AA; Holding AN; Bridge KS; Zhang C; Wang J; Mi J-Q; Lock RB; de Bock CE; Jing D, 2024, 'PU.1 eviction at lymphocyte-specific chromatin domains mediates glucocorticoid response in acute lymphoblastic leukemia', Nature Communications, 15, pp. 9697, http://dx.doi.org/10.1038/s41467-024-54096-2

Huang Y; de Bock CE, 2024, 'Overcoming a T-ALL order: A comprehensive study linking genomics to clinical outcomes', HemaSphere, 8, pp. e70027, http://dx.doi.org/10.1002/hem3.70027

Zhang Q; Li MK; Hu XY; Wu YX; Wang YY; Zhao PP; Cheng LN; Yu RH; Zhang XD; Chen S; Zhu ZM; De Bock CE; Thorne RF, 2024, 'The tumor suppressor Fat1 is dispensable for normal murine hematopoiesis', Journal of Leukocyte Biology, 116, pp. 909 - 914, http://dx.doi.org/10.1093/jleuko/qiae128

Kosasih HJ; de Bock CE, 2024, 'Less is more: Depleting myeloid-biased HSCs to restore immune function', HemaSphere, 8, pp. e125, http://dx.doi.org/10.1002/hem3.125

de Bock CE; Cools J, 2024, 'Selective targeting of malignant T cells', Nature Cancer, 5, pp. 1 - 2, http://dx.doi.org/10.1038/s43018-024-00778-1

de Bock CE, 2024, 'A new mouse model highlights the need for better JAK inhibitors in myeloproliferative neoplasms', HemaSphere, 8, pp. e66 - e66, http://dx.doi.org/10.1002/hem3.66

Randall J; Evans K; Watts B; Kosasih HJ; Smith CM; Earley EJ; Erickson SW; Jocoy EL; Bult CJ; Teicher BA; de Bock CE; Smith MA; Lock RB, 2024, 'In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts', Experimental Hematology, 132, pp. 104176, http://dx.doi.org/10.1016/j.exphem.2024.104176

Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD; Valdes Mora F, 2024, 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma', Journal of Clinical Investigation, 134, pp. e170329, http://dx.doi.org/10.1172/JCI170329

Kosasih HJ; Healey G; Brennan MS; Bjelosevic S; Sadras T; Jalud FB; Ibnat T; Ng AP; Mayoh C; Mao J; Tax G; Ludlow LEA; Johnstone RW; Herold MJ; Khaw SL; de Bock CE; Ekert PG, 2024, 'A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax', HemaSphere, 8, pp. e1, http://dx.doi.org/10.1002/hem3.1

De Coninck S; De Smedt R; Lintermans B; Reunes L; Kosasih HJ; Reekmans A; Brown LM; Van Roy N; Palhais B; Roels J; Van der Linden M; Van Dorpe J; Ntziachristos P; Van Delft FW; Mansour MR; Pieters T; Lammens T; De Moerloose B; De Bock CE; Goossens S; Van Vlierberghe P, 2023, 'Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.', Haematologica, 109, http://dx.doi.org/10.3324/haematol.2023.283981

Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M; Moles Meler E, 2023, 'Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia', Science translational medicine, 15, pp. eabm1262 - eabm1262, http://dx.doi.org/10.1126/scitranslmed.abm1262

Germon ZP; Sillar JR; Mannan A; Duchatel RJ; Staudt D; Murray HC; Findlay IJ; Jackson ER; McEwen HP; Douglas AM; McLachlan T; Schjenken JE; Skerrett-Byrne DA; Huang H; Melo-Braga MN; Plank MW; Alvaro F; Chamberlain J; De Iuliis G; Aitken RJ; Nixon B; Wei AH; Enjeti AK; Huang Y; Lock RB; Larsen MR; Lee H; Vaghjiani V; Cain JE; de Bock CE; Verrills NM; Dun MD, 2023, 'Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies', Science Signaling, 16, pp. 1 - 18, http://dx.doi.org/10.1126/scisignal.abp9586

Sadras T; Jalud FB; Kosasih HJ; Horne CR; Brown LM; El-Kamand S; de Bock CE; McAloney L; Ng AP; Davidson NM; Ludlow LEA; Oshlack A; Cowley MJ; Khaw SL; Murphy JM; Ekert PG, 2023, 'Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL', Leukemia, 37, pp. 1 - 5, http://dx.doi.org/10.1038/s41375-023-01843-x

Walia Y; de Bock CE; Huang Y, 2023, 'The landscape of alterations affecting epigenetic regulators in T-cell acute lymphoblastic leukemia: Roles in leukemogenesis and therapeutic opportunities', International Journal of Cancer, 154, pp. 1522 - 1536, http://dx.doi.org/10.1002/ijc.34819

Roche CD; Lin H; Huang Y; de Bock CE; Beck D; Xue M; Gentile C, 2023, '3D bioprinted alginate-gelatin hydrogel patches containing cardiac spheroids recover heart function in a mouse model of myocardial infarction', Bioprinting, 30, pp. e00263 - e00263, http://dx.doi.org/10.1016/j.bprint.2023.e00263

Omari SA; Kosasih HJ; Chung T; de Bock CE, 2023, 'In vitro and in vivo modelling of mutant JAK3/STAT5 signaling in leukemia', Heliyon, 9, http://dx.doi.org/10.1016/j.heliyon.2023.e22085

Mortlock DP; Fang ZM; Chandler KJ; Hou Y; Bickford LR; de Bock CE; Eapen V; Clarke RA, 2022, 'Transcriptional Interference Regulates the Evolutionary Development of Speech', Genes, 13, http://dx.doi.org/10.3390/genes13071195

Pearson HCL; Hunt KV; Trahair TN; Lock RB; Lee HJ; De Bock CE, 2022, 'The Promise of Single-cell Technology in Providing New Insights into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia', HemaSphere, 6, pp. E734, http://dx.doi.org/10.1097/HS9.0000000000000734

Omari SA; Geraghty DP; Khalafallah AA; Venkat P; Shegog YM; Ragg SJ; de Bock CE; Adams MJ, 2022, 'Optimized flow cytometric detection of transient receptor potential vanilloid-1 (TRPV1) in human hematological malignancies', Medical Oncology, 39, pp. 81, http://dx.doi.org/10.1007/s12032-022-01678-z

Page EC; Heatley SL; Eadie LN; McClure BJ; de Bock CE; Omari S; Yeung DT; Hughes TP; Thomas PQ; White DL, 2022, 'HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort', Oncogene, 41, pp. 797 - 808, http://dx.doi.org/10.1038/s41388-021-02126-4

Van Thillo Q; De Bie J; Seneviratne JA; Demeyer S; Omari S; Balachandran A; Zhai V; Tam WL; Sweron B; Geerdens E; Gielen O; Provost S; Segers H; Boeckx N; Marshall GM; Cheung BB; Isobe K; Kato I; Takita J; Amos TG; Deveson IW; McCalmont H; Lock RB; Oxley EP; Garwood MM; Dickins RA; Uyttebroeck A; Carter DR; Cools J; de Bock CE, 2021, 'Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia', Nature Communications, 12, pp. 4164, http://dx.doi.org/10.1038/s41467-021-24442-9

de Bock CE; Cools J, 2021, 'BETter insight into PRC2-mutated T-ALL', Blood, 138, pp. 1787 - 1788, http://dx.doi.org/10.1182/blood.2021012677

Verbeke D; Demeyer S; Prieto C; de Bock CE; de Bie J; Gielen O; Jacobs K; Mentens N; Verhoeven BM; Uyttebroeck A; Boeckx N; de Keersmaecker K; Maertens J; Segers H; Cools J, 2021, 'The XPO1 inhibitor KPT-8602 synergizes with dexamethasone in acute lymphoblastic Leukemia', Clinical Cancer Research, 26, pp. 5747 - 5758, http://dx.doi.org/10.1158/1078-0432.CCR-20-1315

Connerty P; Moles E; de Bock CE; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB; Moles Meler E, 2021, 'Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for t(8;21) pediatric acute myeloid leukemia', Pharmaceutics, 13, pp. 1681, http://dx.doi.org/10.3390/pharmaceutics13101681

Murray HC; Enjeti AK; Kahl RGS; Flanagan HM; Sillar J; Skerrett-Byrne DA; Al Mazi JG; Au GG; de Bock CE; Evans K; Smith ND; Anderson A; Nixon B; Lock RB; Larsen MR; Verrills NM; Dun MD, 2021, 'Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia', Leukemia, 35, pp. 1782 - 1787, http://dx.doi.org/10.1038/s41375-020-01050-y

Connerty P; Lock RB; de Bock CE, 2020, 'Long Non-coding RNAs: Major Regulators of Cell Stress in Cancer', Frontiers in Oncology, 10, http://dx.doi.org/10.3389/fonc.2020.00285

Thorne RF; Wang Y; Zhang Y; Jing X; Zhang XD; de Bock CE; Oliveira CS, 2020, 'Evaluating nuclear translocation of surface receptors: recommendations arising from analysis of CD44', Histochemistry and Cell Biology, 153, pp. 77 - 87, http://dx.doi.org/10.1007/s00418-019-01835-y

Dun MD; Mannan A; Rigby CJ; Butler S; Toop HD; Beck D; Connerty P; Sillar J; Kahl RGS; Duchatel RJ; Germon Z; Faulkner S; Chi M; Skerrett-Byrne D; Murray HC; Flanagan H; Almazi JG; Hondermarck H; Nixon B; De Iuliis G; Chamberlain J; Alvaro F; de Bock CE; Morris JC; Enjeti AK; Verrills NM, 2020, 'Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia', Leukemia, 34, http://dx.doi.org/10.1038/s41375-020-0814-0

Laukkanen S; Oksa L; Nikkilä A; Lahnalampi M; Parikka M; Seki M; Takita J; Degerman S; de Bock CE; Heinäniemi M; Lohi O, 2020, 'SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome', Leukemia and Lymphoma, 61, pp. 3089 - 3100, http://dx.doi.org/10.1080/10428194.2020.1804560

Broux M; Prieto C; Demeyer S; Bempt MV; Alberti-Servera L; Lodewijckx I; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; De Bock CE; Cools J, 2019, 'Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia', Blood, 134, pp. 1323 - 1336, http://dx.doi.org/10.1182/blood.2019000015

Ahmed AF; de Bock CE; Sontag E; Hondermarck H; Lincz LF; Thorne RF, 2019, 'FAT1 cadherin controls neuritogenesis during NTera2 cell differentiation', Biochemical and Biophysical Research Communications, 514, pp. 625 - 631, http://dx.doi.org/10.1016/j.bbrc.2019.04.197

de Bock CE; Down M; Baidya K; Sweron B; Boyd AW; Fiers M; Burns GF; Molloy TJ; Lock RB; Soulier J; Taghon T; Van Vlierberghe P; Cools J; Holst J; Thorne RF, 2019, 'T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development', Haematologica, 104, pp. e204 - e207, http://dx.doi.org/10.3324/haematol.2018.198424

Habets RA; De Bock CE; Serneels L; Lodewijckx I; Verbeke D; Nittner D; Narlawar R; Demeyer S; Dooley J; Liston A; Taghon T; Cools J; De Strooper B, 2019, 'Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition', Science Translational Medicine, 11, http://dx.doi.org/10.1126/scitranslmed.aau6246

Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD, 2018, 'Correction to: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia (Leukemia, (2018), 32, 3, (788-800), 10.1038/leu.2017.276)', Leukemia, 32, pp. 2731, http://dx.doi.org/10.1038/s41375-018-0241-7

Verboom K; Van Loocke W; Volders PJ; Decaesteker B; Avila Cobos F; Bornschein S; De Bock CE; Kalender Atak Z; Clappier E; Aerts S; Cools J; Soulier J; Taghon T; Van Vlierberghe P; Vandesompele J; Speleman F; Durinck K, 2018, 'A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing', Haematologica, 103, pp. e585 - e589, http://dx.doi.org/10.3324/haematol.2018.190587

Baens M; Stirparo R; Lampi Y; Verbeke D; Vandepoel R; Cools J; Marynen P; de Bock CE; Bornschein S, 2018, 'Malt1 self-cleavage is critical for regulatory T cell homeostasis and anti-tumor immunity in mice', European Journal of Immunology, 48, pp. 1728 - 1738, http://dx.doi.org/10.1002/eji.201847597

Vicente C; Stirparo R; Demeyer S; De Bock CE; Gielen O; Atkins M; Yan J; Halder G; Hassan BA; Cools J, 2018, 'The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models', Journal of Hematology and Oncology, 11, pp. 108, http://dx.doi.org/10.1186/s13045-018-0650-0

Vanden Bempt M; Demeyer S; Broux M; De Bie J; Bornschein S; Mentens N; Vandepoel R; Geerdens E; Radaelli E; Bornhauser BC; Kulozik AE; Meijerink JP; Bourquin JP; de Bock CE; Cools J, 2018, 'Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia', Cancer Cell, 34, pp. 271 - 285.e7, http://dx.doi.org/10.1016/j.ccell.2018.07.007

de Bock CE; Cools J, 2018, 'JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia', Molecular and Cellular Oncology, 5, pp. e1458014, http://dx.doi.org/10.1080/23723556.2018.1458014

de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Bempt MV; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J, 2018, 'HOXA9 cooperates with activated JAK/STAT signaling to drive leukemia development', Cancer Discovery, 8, pp. 616 - 631, http://dx.doi.org/10.1158/2159-8290.CD-17-0583

Bornschein S; Demeyer S; Stirparo R; Gielen O; Vicente C; Geerdens E; Ghesquière B; Aerts S; Cools J; De Bock CE, 2018, 'Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system', Leukemia, 32, pp. 941 - 951, http://dx.doi.org/10.1038/leu.2017.328

Degryse S; De Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD, 2018, 'Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia', Leukemia, 32, pp. 788 - 800, http://dx.doi.org/10.1038/leu.2017.276

Degryse S; Bornschein S; De Bock CE; Leroy E; Bempt MV; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J, 2018, 'Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL', Blood, 131, pp. 421 - 425, http://dx.doi.org/10.1182/blood-2017-07-797597

Pajic M; Froio D; Daly S; Doculara L; Millar E; Graham PH; Drury A; Steinmann A; De Bock CE; Boulghourjian A; Zaratzian A; Carroll S; Toohey J; O'Toole SA; Harris AL; Buffa FM; Gee HE; Hollway GE; Molloy TJ, 2018, 'miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense', Cancer Research, 78, pp. 501 - 515, http://dx.doi.org/10.1158/0008-5472.CAN-16-3105

de Bock CE; Hughes MR; Snyder K; Alley S; Sadeqzadeh E; Dun MD; McNagny KM; Molloy TJ; Hondermarck H; Thorne RF, 2017, 'Protein interaction screening identifies SH3RF1 as a new regulator of FAT1 protein levels', FEBS Letters, 591, pp. 667 - 678, http://dx.doi.org/10.1002/1873-3468.12569

Dagklis A; Demeyer S; DeBie J; Radaelli E; Pauwels D; Degryse S; Gielen O; Vicente C; Vandepoel R; Geerdens E; Uyttebroeck A; Boeckx N; De Bock CE; Cools J, 2016, 'Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors', Blood, 128, pp. 2642 - 2654, http://dx.doi.org/10.1182/blood-2016-03-703454

De Bock CE; Thorne RF, 2016, 'A mitochondrial brake on vascular repair', Nature, 539, pp. 503 - 505, http://dx.doi.org/10.1038/nature20476

Vanden Bempt M; Demeyer S; Mentens N; Geerdens E; De Bock CE; Wlodarska I; Cools J, 2016, 'Generation of the Fip1l1-Pdgfra fusion gene using CRISPR/Cas genome editing', Leukemia, 30, pp. 1913 - 1916, http://dx.doi.org/10.1038/leu.2016.62

Durinck K; Van Loocke W; Van Der Meulen J; Van De Walle I; Ongenaert M; Rondou P; Wallaert A; De Bock CE; Van Roy N; Poppe B; Cools J; Soulier J; Taghon T; Speleman F; Van Vlierberghe P, 2015, 'Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia', Leukemia, 29, pp. 2317 - 2327, http://dx.doi.org/10.1038/leu.2015.162

Back to profile page